Oral Plenary

18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial

Pub Date : 2020-11-01 DOI: 10.1136/ijgc-2020-igcs.18 P. Harter, D. Petran, G. Scambia, E. Ortega, I. Tsibulak, S. Nagao, I. Vergote, J. Meunier, F. Priou, R. Sverdlin, T. Milenkova, I. Ray-Coquard

1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial

Pub Date : 2020-11-01 DOI: 10.1136/ijgc-2020-igcs.1 J. Ledermann, N. Colombo, A. Oza, K. Fujiwara, M. Birrer, L. Randall, E. Poddubskaya, G. Scambia, YV Shparyk, M. Lim, J. Sohn, K. Yonemori, R. Stewart, Xijun Zhang, J. P. Smith, C. Linn, B. Monk

16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer

Pub Date : 2020-11-01 DOI: 10.1136/ijgc-2020-igcs.16 A. A. Secord, M. Bookman, R. E. Coleman, Minh H. Dinh, N. Khandelwal, K. Benjamin, Rajesh Kamalakar, Danielle Sullivan, David Cella